Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma

Raed A. Dweik, Ronald L. Sorkness, Sally Wenzel, Jeffrey Hammel, Douglas Curran-Everett, Suzy A A Comhair, Eugene Bleecker, William Busse, William Calhoun, Mario Castro, Kian Fan Chung, Elliot Israel, Nizar Jarjour, Wendy Moore, Stephen Peters, Gerald Teague, Benjamin Gaston, Serpil C. Erzurum

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Rationale: Exhaled nitric oxide (FENO) is a biomarker of airway inflammation in mild to moderate asthma. However, whether FENO levels are informative regarding airway inflammation in patients with severe asthma,whoare refractory to conventional treatment, is unknown. Here, we hypothesized that classification of severe asthma based on airway inflammation as defined by FENO levels would identify a more reactive, at-risk asthma phenotype. Methods: FENO and major features of asthma, including airway inflammation, airflow limitation, hyperinflation, hyperresponsiveness, and atopy, were determined in 446 individuals with various degrees of asthma severity (175 severe, 271 nonsevere) and 49 healthy subjects enrolled in the Severe Asthma Research Program. Measurements and Main Results: FENO levels were similar among patients with severe and nonsevere asthma. The proportion of individuals with high FENO levels (>35 ppb) was the same (40%) among groups despite greater corticosteroid therapy in severe asthma. All patients with asthma and high FENO had more airway reactivity (maximal reversal in response to bronchodilator administration and by methacholine challenge), more evidence of allergic airway inflammation (sputum eosinophils), more evidence of atopy (positive skin tests, higher serum IgE and blood eosinophils), and more hyperinflation, but decreased awareness of their symptoms. High FENO identified those patientswith severeasthmacharacterized by the greatest airflow obstruction and hyperinflation and most frequent use of emergency care. Conclusions: Grouping of asthma by FENO provides an independent classification of asthma severity, and among patients with severe asthma identifies the most reactive and worrisome asthma phenotype.

Original languageEnglish (US)
Pages (from-to)1033-1041
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume181
Issue number10
DOIs
StatePublished - May 15 2010
Externally publishedYes

Fingerprint

Nitric Oxide
Asthma
Phenotype
Inflammation
Eosinophils
Methacholine Chloride
Bronchodilator Agents
Emergency Medical Services
Skin Tests
Sputum
Immunoglobulin E
Healthy Volunteers
Adrenal Cortex Hormones
Biomarkers

Keywords

  • Airway reactivity
  • Exhaled breath
  • Nitric oxide
  • Phenotype
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Dweik, R. A., Sorkness, R. L., Wenzel, S., Hammel, J., Curran-Everett, D., Comhair, S. A. A., ... Erzurum, S. C. (2010). Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. American Journal of Respiratory and Critical Care Medicine, 181(10), 1033-1041. https://doi.org/10.1164/rccm.200905-0695OC

Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. / Dweik, Raed A.; Sorkness, Ronald L.; Wenzel, Sally; Hammel, Jeffrey; Curran-Everett, Douglas; Comhair, Suzy A A; Bleecker, Eugene; Busse, William; Calhoun, William; Castro, Mario; Chung, Kian Fan; Israel, Elliot; Jarjour, Nizar; Moore, Wendy; Peters, Stephen; Teague, Gerald; Gaston, Benjamin; Erzurum, Serpil C.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 181, No. 10, 15.05.2010, p. 1033-1041.

Research output: Contribution to journalArticle

Dweik, RA, Sorkness, RL, Wenzel, S, Hammel, J, Curran-Everett, D, Comhair, SAA, Bleecker, E, Busse, W, Calhoun, W, Castro, M, Chung, KF, Israel, E, Jarjour, N, Moore, W, Peters, S, Teague, G, Gaston, B & Erzurum, SC 2010, 'Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma', American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 10, pp. 1033-1041. https://doi.org/10.1164/rccm.200905-0695OC
Dweik, Raed A. ; Sorkness, Ronald L. ; Wenzel, Sally ; Hammel, Jeffrey ; Curran-Everett, Douglas ; Comhair, Suzy A A ; Bleecker, Eugene ; Busse, William ; Calhoun, William ; Castro, Mario ; Chung, Kian Fan ; Israel, Elliot ; Jarjour, Nizar ; Moore, Wendy ; Peters, Stephen ; Teague, Gerald ; Gaston, Benjamin ; Erzurum, Serpil C. / Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 181, No. 10. pp. 1033-1041.
@article{d261ca155d854ed3b4f49d787a63545c,
title = "Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma",
abstract = "Rationale: Exhaled nitric oxide (FENO) is a biomarker of airway inflammation in mild to moderate asthma. However, whether FENO levels are informative regarding airway inflammation in patients with severe asthma,whoare refractory to conventional treatment, is unknown. Here, we hypothesized that classification of severe asthma based on airway inflammation as defined by FENO levels would identify a more reactive, at-risk asthma phenotype. Methods: FENO and major features of asthma, including airway inflammation, airflow limitation, hyperinflation, hyperresponsiveness, and atopy, were determined in 446 individuals with various degrees of asthma severity (175 severe, 271 nonsevere) and 49 healthy subjects enrolled in the Severe Asthma Research Program. Measurements and Main Results: FENO levels were similar among patients with severe and nonsevere asthma. The proportion of individuals with high FENO levels (>35 ppb) was the same (40{\%}) among groups despite greater corticosteroid therapy in severe asthma. All patients with asthma and high FENO had more airway reactivity (maximal reversal in response to bronchodilator administration and by methacholine challenge), more evidence of allergic airway inflammation (sputum eosinophils), more evidence of atopy (positive skin tests, higher serum IgE and blood eosinophils), and more hyperinflation, but decreased awareness of their symptoms. High FENO identified those patientswith severeasthmacharacterized by the greatest airflow obstruction and hyperinflation and most frequent use of emergency care. Conclusions: Grouping of asthma by FENO provides an independent classification of asthma severity, and among patients with severe asthma identifies the most reactive and worrisome asthma phenotype.",
keywords = "Airway reactivity, Exhaled breath, Nitric oxide, Phenotype, Severe asthma",
author = "Dweik, {Raed A.} and Sorkness, {Ronald L.} and Sally Wenzel and Jeffrey Hammel and Douglas Curran-Everett and Comhair, {Suzy A A} and Eugene Bleecker and William Busse and William Calhoun and Mario Castro and Chung, {Kian Fan} and Elliot Israel and Nizar Jarjour and Wendy Moore and Stephen Peters and Gerald Teague and Benjamin Gaston and Erzurum, {Serpil C.}",
year = "2010",
month = "5",
day = "15",
doi = "10.1164/rccm.200905-0695OC",
language = "English (US)",
volume = "181",
pages = "1033--1041",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma

AU - Dweik, Raed A.

AU - Sorkness, Ronald L.

AU - Wenzel, Sally

AU - Hammel, Jeffrey

AU - Curran-Everett, Douglas

AU - Comhair, Suzy A A

AU - Bleecker, Eugene

AU - Busse, William

AU - Calhoun, William

AU - Castro, Mario

AU - Chung, Kian Fan

AU - Israel, Elliot

AU - Jarjour, Nizar

AU - Moore, Wendy

AU - Peters, Stephen

AU - Teague, Gerald

AU - Gaston, Benjamin

AU - Erzurum, Serpil C.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Rationale: Exhaled nitric oxide (FENO) is a biomarker of airway inflammation in mild to moderate asthma. However, whether FENO levels are informative regarding airway inflammation in patients with severe asthma,whoare refractory to conventional treatment, is unknown. Here, we hypothesized that classification of severe asthma based on airway inflammation as defined by FENO levels would identify a more reactive, at-risk asthma phenotype. Methods: FENO and major features of asthma, including airway inflammation, airflow limitation, hyperinflation, hyperresponsiveness, and atopy, were determined in 446 individuals with various degrees of asthma severity (175 severe, 271 nonsevere) and 49 healthy subjects enrolled in the Severe Asthma Research Program. Measurements and Main Results: FENO levels were similar among patients with severe and nonsevere asthma. The proportion of individuals with high FENO levels (>35 ppb) was the same (40%) among groups despite greater corticosteroid therapy in severe asthma. All patients with asthma and high FENO had more airway reactivity (maximal reversal in response to bronchodilator administration and by methacholine challenge), more evidence of allergic airway inflammation (sputum eosinophils), more evidence of atopy (positive skin tests, higher serum IgE and blood eosinophils), and more hyperinflation, but decreased awareness of their symptoms. High FENO identified those patientswith severeasthmacharacterized by the greatest airflow obstruction and hyperinflation and most frequent use of emergency care. Conclusions: Grouping of asthma by FENO provides an independent classification of asthma severity, and among patients with severe asthma identifies the most reactive and worrisome asthma phenotype.

AB - Rationale: Exhaled nitric oxide (FENO) is a biomarker of airway inflammation in mild to moderate asthma. However, whether FENO levels are informative regarding airway inflammation in patients with severe asthma,whoare refractory to conventional treatment, is unknown. Here, we hypothesized that classification of severe asthma based on airway inflammation as defined by FENO levels would identify a more reactive, at-risk asthma phenotype. Methods: FENO and major features of asthma, including airway inflammation, airflow limitation, hyperinflation, hyperresponsiveness, and atopy, were determined in 446 individuals with various degrees of asthma severity (175 severe, 271 nonsevere) and 49 healthy subjects enrolled in the Severe Asthma Research Program. Measurements and Main Results: FENO levels were similar among patients with severe and nonsevere asthma. The proportion of individuals with high FENO levels (>35 ppb) was the same (40%) among groups despite greater corticosteroid therapy in severe asthma. All patients with asthma and high FENO had more airway reactivity (maximal reversal in response to bronchodilator administration and by methacholine challenge), more evidence of allergic airway inflammation (sputum eosinophils), more evidence of atopy (positive skin tests, higher serum IgE and blood eosinophils), and more hyperinflation, but decreased awareness of their symptoms. High FENO identified those patientswith severeasthmacharacterized by the greatest airflow obstruction and hyperinflation and most frequent use of emergency care. Conclusions: Grouping of asthma by FENO provides an independent classification of asthma severity, and among patients with severe asthma identifies the most reactive and worrisome asthma phenotype.

KW - Airway reactivity

KW - Exhaled breath

KW - Nitric oxide

KW - Phenotype

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=77952206441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952206441&partnerID=8YFLogxK

U2 - 10.1164/rccm.200905-0695OC

DO - 10.1164/rccm.200905-0695OC

M3 - Article

VL - 181

SP - 1033

EP - 1041

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -